Meta analysis of the intervention of Baduanjin in middle-aged and elderly patients with essential hypertension

IF 4 3区医学 Q1 INTEGRATIVE & COMPLEMENTARY MEDICINE

Complementary therapies in medicine Pub Date : 2025-12-01 Epub Date: 2025-10-26 DOI:10.1016/j.ctim.2025.103258

Tianhao Zhang, Li Chen, Mingang Guo

{"title":"Meta analysis of the intervention of Baduanjin in middle-aged and elderly patients with essential hypertension","authors":"Tianhao Zhang, Li Chen, Mingang Guo","doi":"10.1016/j.ctim.2025.103258","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><div>We systematically evaluated Baduanjin efficacy for improving blood pressure, lipid metabolism, and heart rate in middle-aged and elderly patients with essential hypertension, explored its physiological mechanisms, and assessed evidence quality using GRADE criteria.</div></div><div><h3>Methods</h3><div>We searched CNKI, PubMed, and Web of Science (January 2010–March 2025) for randomized controlled trials (RCTs). Twenty-four RCTs (1994 participants, aged 35–80 years, interventions: 3–12 months) met inclusion criteria. Primary outcomes: systolic blood pressure (SBP), diastolic blood pressure (DBP), triglycerides (TG), total cholesterol (TC), heart rate (HR). We assessed risk of bias using Cochrane/PEDro tools and performed meta-analysis using random-effects models. Sensitivity analyses excluded studies with high bias risk, non-standard interventions, or inconsistent control groups.</div></div><div><h3>Results</h3><div>Baduanjin significantly reduced SBP by 8.3 mmHg (3 months), 11.4 mmHg (6 months), and 5.4 mmHg (12 months); DBP by 3.9 mmHg (3 months), 6.2 mmHg (6 months), and 4.1 mmHg (12 months). It improved TG (SMD = −0.34 [95 % CI: −0.49, −0.19]), TC (SMD = −0.92 [−1.49, −0.34]; high heterogeneity), and HR (SMD = −1.07 [−1.76, −0.38]). GRADE rated evidence quality as moderate (most BP outcomes), low (TG), and very low (TC), primarily due to methodological limitations.</div></div><div><h3>Conclusion</h3><div>Baduanjin is an effective, low-cost adjunct intervention for essential hypertension, particularly reducing blood pressure within 3–6 months. We recommend implementing 3–6-month Baduanjin programs (5–6 sessions/week) in clinical practice. Benefits on lipid metabolism and heart rate require confirmation via higher-quality trials. Future research should standardize protocols and explore mechanisms.</div></div>","PeriodicalId":10545,"journal":{"name":"Complementary therapies in medicine","volume":"95 ","pages":"Article 103258"},"PeriodicalIF":4.0000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Complementary therapies in medicine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0965229925001347","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/10/26 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"INTEGRATIVE & COMPLEMENTARY MEDICINE","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose

We systematically evaluated Baduanjin efficacy for improving blood pressure, lipid metabolism, and heart rate in middle-aged and elderly patients with essential hypertension, explored its physiological mechanisms, and assessed evidence quality using GRADE criteria.

Methods

We searched CNKI, PubMed, and Web of Science (January 2010–March 2025) for randomized controlled trials (RCTs). Twenty-four RCTs (1994 participants, aged 35–80 years, interventions: 3–12 months) met inclusion criteria. Primary outcomes: systolic blood pressure (SBP), diastolic blood pressure (DBP), triglycerides (TG), total cholesterol (TC), heart rate (HR). We assessed risk of bias using Cochrane/PEDro tools and performed meta-analysis using random-effects models. Sensitivity analyses excluded studies with high bias risk, non-standard interventions, or inconsistent control groups.

Results

Baduanjin significantly reduced SBP by 8.3 mmHg (3 months), 11.4 mmHg (6 months), and 5.4 mmHg (12 months); DBP by 3.9 mmHg (3 months), 6.2 mmHg (6 months), and 4.1 mmHg (12 months). It improved TG (SMD = −0.34 [95 % CI: −0.49, −0.19]), TC (SMD = −0.92 [−1.49, −0.34]; high heterogeneity), and HR (SMD = −1.07 [−1.76, −0.38]). GRADE rated evidence quality as moderate (most BP outcomes), low (TG), and very low (TC), primarily due to methodological limitations.

Conclusion

Baduanjin is an effective, low-cost adjunct intervention for essential hypertension, particularly reducing blood pressure within 3–6 months. We recommend implementing 3–6-month Baduanjin programs (5–6 sessions/week) in clinical practice. Benefits on lipid metabolism and heart rate require confirmation via higher-quality trials. Future research should standardize protocols and explore mechanisms.

查看原文本刊更多论文

八段金对中老年原发性高血压患者干预的Meta分析。

目的：系统评价八段金改善中老年原发性高血压患者血压、脂质代谢和心率的疗效，探讨其生理机制，并采用GRADE标准评价证据质量。方法：检索中国知网、PubMed和Web of Science（2010年1月- 2025年3月）的随机对照试验（rct）。24项随机对照试验（1994名受试者，年龄35-80岁，干预时间3-12个月）符合纳入标准。主要结局：收缩压（SBP）、舒张压（DBP）、甘油三酯（TG）、总胆固醇（TC）、心率（HR）。我们使用Cochrane/PEDro工具评估偏倚风险，并使用随机效应模型进行meta分析。敏感性分析排除了高偏倚风险、非标准干预或不一致对照组的研究。结果：八段金显著降低收缩压8.3mmHg（3个月）、11.4mmHg（6个月）、5.4mmHg（12个月）；DBP降低3.9mmHg（3个月）、6.2mmHg（6个月）和4.1mmHg（12个月）。改善TG （SMD = -0.34 [95% CI: -0.49, -0.19]）、TC （SMD = -0.92[-1.49, -0.34]；异质性高）和HR （SMD = -1.07[-1.76, -0.38]）。GRADE将证据质量评定为中等（大多数血压结果）、低（TG）和极低（TC），主要是由于方法学的局限性。结论：八段金是治疗原发性高血压的一种有效、低成本的辅助干预手段，对3 ~ 6个月的降压效果显著。我们建议在临床实践中实施3-6个月的八段金项目（5-6次/周）。对脂质代谢和心率的益处需要通过更高质量的试验来证实。未来的研究应规范协议，探索机制。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Complementary therapies in medicine 医学-全科医学与补充医学

CiteScore

8.60

自引率

2.80%

发文量

101

审稿时长

112 days

期刊介绍： Complementary Therapies in Medicine is an international, peer-reviewed journal that has considerable appeal to anyone who seeks objective and critical information on complementary therapies or who wishes to deepen their understanding of these approaches. It will be of particular interest to healthcare practitioners including family practitioners, complementary therapists, nurses, and physiotherapists; to academics including social scientists and CAM researchers; to healthcare managers; and to patients. Complementary Therapies in Medicine aims to publish valid, relevant and rigorous research and serious discussion articles with the main purpose of improving healthcare.